|
Jul 28
|
Mesoblast Limited (MESO) Launches First Cell Therapy for Children
|
|
Jul 24
|
ASX Growth Stocks With High Insider Stakes
|
|
Jul 24
|
High Growth Tech Stocks To Watch In Australia July 2025
|
|
Jul 22
|
Mesoblast Limited (MESO) Is Up 40.59% in One Week: What You Should Know
|
|
Jul 21
|
[Latest] Global Cardiac Tissue Engineering Market Size/Share Worth USD 2,943.92 Million by 2034 at a 16.65% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
|
|
Jul 18
|
Successful Commercial Launch of Ryoncil®
|
|
Jul 1
|
Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
|
|
Jun 29
|
Mesoblast (MESO) Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for Ryoncil
|
|
Apr 17
|
Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives
|
|
Mar 12
|
Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
|
|
Mar 10
|
Mesoblast Limited (MESO): Among the Best Australian Stocks to Buy According to Billionaires
|
|
Mar 6
|
Mesoblast Added to S&P/ASX 200 INDEX
|
|
Mar 4
|
While Mesoblast (ASX:MSB) shareholders have made 667% in 1 year, increasing losses might now be front of mind as stock sheds 8.7% this week
|
|
Feb 13
|
Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
|
|
Feb 12
|
Domino's Pizza Enterprises And 2 Other ASX Stocks That Might Be Trading Below Fair Value
|
|
Jan 3
|
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
|
|
Jan 3
|
Exploring 3 High Growth Tech Stocks In Australia
|